skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Review

(1488) Views  (634) Full article downloads

Authors: Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Published Date September 2010 Volume 2010:6 Pages 855 - 867
DOI: http://dx.doi.org/10.2147/VHRM.S7402

Juan V Llau1, Raquel Ferrandis1, Pilar Sierra2, Aurelio Gómez-Luque3
1Department of Anaesthesiology and Critical Care Medicine, Hospital Clínic Universitari, València, Spain; 2Department of Anaesthesiology, Fundació Puigvert, Barcelona, Spain; 3Department of Anaesthesiology and Critical Care Medicine, Hospital Clínico Universitario, Málaga, Spain

Abstract: The management of patients scheduled for surgery with a coronary stent, and receiving 1 or more antiplatelet drugs, has many controversies. The premature discontinuation of antiplatelet drugs substantially increases the risk of stent thrombosis (ST), myocardial infarction, and cardiac death, and surgery under an altered platelet function could also lead to an increased risk of bleeding in the perioperative period. Because of the conflict in the recommendations, this article reviews the current antiplatelet protocols after positioning a coronary stent, the evidence of increased risk of ST associated with the withdrawal of antiplatelet drugs and increased bleeding risk associated with its maintenance, the different perioperative antiplatelet protocols when patients are scheduled for surgery or need an urgent operation, and the therapeutic options if excessive bleeding occurs.

Keywords: stent thrombosis, antiplatelet agents, aspirin, clopidogrel, surgical bleeding, perioperative management






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
New class of agents for treatment of hypertension: Focus on direct renin inhibition
Small coronary vessel angioplasty: outcomes and technical considerations
Antiplatelet combinations for prevention of atherothrombotic events
Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University